Merck & Co., Inc. ranks near the peer group median, with a broadly solid and relatively even profile. Price behavior is partially reflecting the structural picture, with a moderate gap remaining.
Peer-relative scores, weakest to strongest
Merck & Co., Inc. is a global pharmaceutical company specializing in prescription medicines, vaccines, and animal health products. Its portfolio includes leading oncology and immunology therapies.
Profitability defines the core profile: Merck delivers a ROIC of 21.97% and an operating margin of 32.8%, placing it among the sector’s most efficient capital allocators. The company trades at a discount, with a forward P/E of 12.2x—less than half the peer median—because its growth profile is weaker than competitors. The market’s valuation reflects this growth gap.
Revenue growth is 5% year-over-year, and Merck’s growth score of 28/100 is below peers like Exelixis (60/100) and Illumina (60/100). While the valuation score (80/100) and discount to peer multiples indicate recognition of Merck’s strengths, the lack of growth momentum maintains the discount. Q4 2025’s EPS and revenue beats, along with analyst price target upgrades in early 2026, support operational resilience but have not led to a rerating as growth remains below the sector. Max drawdown of -43.4% indicates exposure to market risk.
Recent external context partly offsets the growth concern. The Q4 2025 earnings beat and analyst upgrades reinforce operational resilience and market confidence. Merck’s accelerated adoption of AI in R&D places it ahead of slower peers, suggesting improved pipeline productivity. However, these factors require sustained revenue acceleration and closing the growth gap versus competitors to affect valuation.
Compared to its peer set, Merck’s profitability and capital returns are among the strongest, but its growth score is at the lower end. The valuation discount is more pronounced than for most peers, with only Bristol-Myers Squibb showing a similar gap. This pattern is partly driven by Merck’s current product cycle and R&D transition, rather than sector-wide pressures alone.
A more constructive outlook would require revenue growth returning to peer median levels and evidence that AI-driven R&D efficiency results in new product launches. Supporting improvement would include sustained analyst confidence and positive earnings momentum. Until then, Merck appears as a discount despite strong fundamentals.
Break down MRK's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.